Register Login

Blog

Follow-up to “FDA Approves Hemophilia A Gene Transfer Therapy”

This is a follow-up to “FDA Approves Hemophilia A Gene Transfer Therapy,’ posted July 3, 2023, with reference to Dr. Emmanuel Favaloro’s comment, added August 9 and citing Valentino LA, Kaczmarek R, Pierce GF, et al. Hemophilia gene therapy: first, do no harm. J Thromb Haemost. 2023: S1538-7836(23)00501-9. doi: 10.1016/j.jtha.2023.06.016. [click for a copy]. The […]
read more

May 2023 Quick Question: DTI

Our May 2023 Quick Question asks, “Which DOAC is a direct thrombin inhibitor? Our 70 respondents chose… Dabigatran [Pradaxa]: 56 [80%] Rivaroxaban [Xarelto]: 3 [4%] Apixaban [Eliquis]: 3 [4%] Warfarin [Coumadin]: 7 [10%] Clopidogrel [Plavix]: [2%] Dabigatran is the direct thrombin inhibitor, whereas rivaroxaban and apixaban are direct anti-Xa inhibitors. Clopidogrel is an antiplatelet antithrombotic. […]
read more